about
Neurologic adverse effects during concomitant treatment with ciprofloxacin, NSAIDS, and chloroquine: possible drug interaction.Do we need an intravenous fluoroquinolone?Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trialsIn vitro antibiotic resistance in bacterial keratitis in London.Pharmacokinetics of ciprofloxacin in the human eye: a clinical study and population pharmacokinetic analysis.An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration.Efficacy and safety of a novel once-daily extended-release ciprofloxacin tablet formulation for treatment of uncomplicated urinary tract infection in women.Predicting human hepatic clearance from in vitro drug metabolism and transport data: a scientific and pharmaceutical perspective for assessing drug-drug interactions.Population pharmacokinetics of ciprofloxacin in neonates and young infants less than three months of age.Absorption of ciprofloxacin in patients with diabetic gastroparesis.Oral bioavailability and pharmacokinetics of ciprofloxacin in patients with AIDS.The new fluoroquinolones: A critical reviewSelective decontamination of the digestive tract in intensive care patients: review and commentary.Inhibition of norfloxacin absorption by dairy products.Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects.The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosingSteady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: penetration of the bronchial mucosa.Antimicrobial Stewardship in the Microbiology Laboratory: Impact of Selective Susceptibility Reporting on Ciprofloxacin Utilization and Susceptibility of Gram-Negative Isolates to Ciprofloxacin in a Hospital Setting.A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection.The emerging threat of multidrug-resistant Gram-negative bacteria in urology.Population Pharmacokinetic Modeling as a Tool To Characterize the Decrease in Ciprofloxacin Free Interstitial Levels Caused by Pseudomonas aeruginosa Biofilm Lung Infection in Wistar Rats.Influences of urinary pH on ciprofloxacin pharmacokinetics in humans and antimicrobial activity in vitro versus those of sparfloxacin.Influence of renal failure on ciprofloxacin pharmacokinetics in rats.Circadian variation in urinary excretion of ciprofloxacin after a single-dose oral administration at 1000 and 2200 hours in human subjectsEffects of cardiopulmonary bypass surgery on intravenous ciprofloxacin dispositionPopulation pharmacokinetics of ciprofloxacin in pediatric and adolescent patients with acute infections.Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients.The effect of urine storage on antiviral and antibiotic compounds in the liquid phase of source-separated urine.Efficacy of Ceftriaxone, Cefepime, Doxycycline, Ciprofloxacin, and Combination Therapy for Vibrio vulnificus Foodborne Septicemia.Comparative in vitro efficacies of various catheter lock solutions.Transport of gemifloxacin, a 4th generation quinolone antibiotic, in the Caco-2 and engineered MDCKII cells, and potential involvement of efflux transporters in the intestinal absorption of the drug.Pharmacokinetics of ciprofloxacin in sheep after single intravenous or intramuscular administration.Bioequivalence of two brands of ciprofloxacin 750 mg tablets (Sarf and Ciprobay) in healthy human volunteers.Pharmacokinetics of ciprofloxacin in patients with acute renal failure undergoing continuous venovenous haemofiltration: influence of concomitant liver cirrhosis.In vivo interaction between ciprofloxacin hydrochloride and the pulp of unripe plantain (Musa paradisiaca).Antibiotic-Induced Changes to the Host Metabolic Environment Inhibit Drug Efficacy and Alter Immune Function.Effect of simulated microgravity on the disposition and tissue penetration of ciprofloxacin in healthy volunteers.Pharmacokinetics and pharmacodynamics of a novel extended-release ciprofloxacin in healthy volunteers.Distribution of ciprofloxacin into the central nervous system in rats with acute renal or hepatic failure.Comparative effects of the immediate and the extended release formulations of ciprofloxacin on normal human intestinal microflora.
P2860
Q33174236-FA2AFC85-039B-4209-AB44-A189927AB0F5Q33606570-261C4AC3-CE30-455B-BC78-E39E88B4E684Q33645202-DC3E3AA5-13E1-4D65-B462-42A135E66EAEQ33954673-CF6F7A67-52DB-43C1-B1CF-A57C92E3D43BQ33979807-BE6F62AB-4068-484C-9075-F6DE5EACDBECQ33982009-DF5A89A6-84D1-4B3B-84D9-3064A2E51342Q34077082-5D9402AB-02F2-43CE-A71F-D99178DF04F2Q34190909-FFAD1F39-10AE-468E-A1AD-33446DA8378DQ34596303-21A04DD4-9275-4CBD-B8D9-1EAE0C75C87CQ35118948-BDD4C77A-0A48-4F87-B412-F6222285DD58Q35137129-D8AABFDA-5DDA-40B2-8CDB-BD638386DD41Q35649595-412141A0-2892-4879-8755-4A75F6C716BDQ35714786-42603F38-76E1-4D7B-B3EF-3213F4DA1EBFQ35826555-CBEB0ABD-6AC4-4039-A840-41E5342A09B4Q35827758-F216AA2B-F301-41E8-8390-ABAA810A1079Q36055013-1AAF55B8-93F3-4D0B-8DFA-AFB5238C1EACQ36757441-C693AE01-37D0-4DC2-9786-58BCAA0D346CQ37218611-800BC9C1-599D-4FEA-B483-C26E5940E6EAQ37733479-C6D82C29-3AF8-4E32-8BA8-3C48B901AC5EQ38579512-9EC2A5F4-0B8B-4689-90EA-156D107C98CDQ38810304-99858182-CAD3-4A71-9591-90E956DC512EQ39470224-97D3082B-2C72-49BE-A829-F9F04CF6C265Q39556635-ADCE136C-6D60-460D-99E5-3C6D71F71162Q39784776-C4631526-7D88-4821-B8C6-9C1260467C67Q39881928-E0C62290-D580-450D-82F9-C2D83EE6E004Q39913232-102DDD6D-852E-4812-8C89-43BB9FFBB7EEQ39936905-F7EE4819-7796-4FDB-825C-23745CDC2D78Q40954809-DC82345D-D1BF-406E-A5C3-19D6A684A256Q41991766-33538071-86BC-43C0-81A2-CCB8C48A3EB0Q42424787-671F1C13-24D4-440B-9E95-009163E6BC28Q42513426-BA0266F0-C2BC-45C4-9C3A-C85500E553ACQ42637703-3404ACDA-C379-4F06-9EFF-24E1F7DE89D5Q42678033-BD0BD35C-1510-4959-B7C4-4EC8C8F889ACQ44094982-DDB4EE87-87EA-4740-ABA2-D5AA12A7CC27Q44742545-D54920E4-47BD-4F77-84F1-88957491E10CQ45975273-ECE212F9-75B1-461D-9F68-745920225377Q46542227-7898653A-9BAC-48F4-8F84-121F0D6AD8F9Q46765980-5AFB872F-DD6D-4C77-9B86-CDE90115A24CQ48159893-86F17863-CE92-48E8-9B17-49E76E9B90B8Q51440064-CBE51435-9E20-4901-A024-A6EA915F9377
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Clinical pharmacokinetics of ciprofloxacin.
@en
type
label
Clinical pharmacokinetics of ciprofloxacin.
@en
prefLabel
Clinical pharmacokinetics of ciprofloxacin.
@en
P2093
P1476
Clinical pharmacokinetics of ciprofloxacin.
@en
P2093
Rotschafer JC
Vance-Bryan K
P304
P356
10.2165/00003088-199019060-00003
P577
1990-12-01T00:00:00Z
P6179
1024055665